357 related articles for article (PubMed ID: 27816693)
1. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
2. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V
J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229
[TBL] [Abstract][Full Text] [Related]
5. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
[TBL] [Abstract][Full Text] [Related]
6. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M
Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878
[TBL] [Abstract][Full Text] [Related]
7. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.
Pokorná Z; Kollárová-Brázdová P; Lenčová-Popelová O; Jirkovský E; Kubeš J; Mazurová Y; Adamcová M; Holečková M; Palička V; Šimůnek T; Štěrba M
Clin Sci (Lond); 2022 Jan; 136(1):139-161. PubMed ID: 34878093
[TBL] [Abstract][Full Text] [Related]
9. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
[TBL] [Abstract][Full Text] [Related]
10.
Pokorna Z; Jirkovsky E; Hlavackova M; Jansova H; Jirkovska A; Lencova-Popelova O; Brazdova P; Kubes J; Sotakova-Kasparova D; Mazurova Y; Adamcova M; Vostatkova L; Holzerova K; Kolar F; Simunek T; Sterba M
Clin Sci (Lond); 2019 Aug; 133(16):1827-1844. PubMed ID: 31409729
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
[TBL] [Abstract][Full Text] [Related]
12. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.
Simůnek T; Sterba M; Popelová O; Kaiserová H; Adamcová M; Hroch M; Hasková P; Ponka P; Gersl V
Br J Pharmacol; 2008 Sep; 155(1):138-48. PubMed ID: 18536744
[TBL] [Abstract][Full Text] [Related]
14. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
[TBL] [Abstract][Full Text] [Related]
15. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
Li W; Xu B; Xu J; Wu XL
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757
[TBL] [Abstract][Full Text] [Related]
16. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M
Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284
[TBL] [Abstract][Full Text] [Related]
17. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
18. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.
Fulbright JM; Egas-Bejar DE; Huh WW; Chandra J
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1297-307. PubMed ID: 26515054
[TBL] [Abstract][Full Text] [Related]
19. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
[TBL] [Abstract][Full Text] [Related]
20. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
